Literature DB >> 21404017

Fundal changes in children receiving Vigabatrin.

Devendra Mishra1, Veena Kalra, Pradeep Venkatesh, Rachna Seth, Sheffali Gulati.   

Abstract

Visual field defects and other abnormalities are reported in patients receiving the newer antiepileptic Vigabatrin (VGB). Field testing in children younger than 6 years and those with mental retardation is difficult. The authors, therefore, studied ophthalmoscopic abnormalities in seven pediatric patients receiving VGB for median duration of 9 month (range, 3-32 months). Abnormal findings were seen in two (33.3%) in the form of surface wrinkling retinopathy and abnormal macular reflexes. The proportion of abnormal findings was in agreement with previous reports. Thus it is concluded that simple ophthalmoscopy by an ophthalmologist picks up the abnormalities due to ocular toxicity of VGB, and helps in rationalizing further AED therapy in the clinic.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21404017     DOI: 10.1007/s12098-011-0388-y

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  8 in total

1.  The ocular side effects of vigabatrin (Sabril): information and guidance for screening.

Authors:  M J Hawker; N J Astbury
Journal:  Eye (Lond)       Date:  2008-05-23       Impact factor: 3.775

2.  Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin.

Authors:  R Mackenzie; A Klistorner
Journal:  BMJ       Date:  1998-01-17

3.  Visual field loss associated with vigabatrin: quantification and relation to dosage.

Authors:  P Hardus; W M Verduin; M Engelsman; P M Edelbroek; J P Segers; T T Berendschot; J S Stilma
Journal:  Epilepsia       Date:  2001-02       Impact factor: 5.864

4.  Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects.

Authors:  R Kälviäinen; I Nousiainen; M Mäntyjärvi; E Nikoskelainen; J Partanen; K Partanen; P Riekkinen
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

5.  Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.

Authors:  Peter Kinirons; Gianpiero L Cavalleri; Dierdre O'Rourke; Colin P Doherty; Irene Reid; Patricia Logan; Brenda Liggan; Norman Delanty
Journal:  Epilepsia       Date:  2006-02       Impact factor: 5.864

6.  Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children.

Authors:  J Raymond Buncic; Carol A Westall; Carole M Panton; J Robert Munn; Leslie D MacKeen; William J Logan
Journal:  Ophthalmology       Date:  2004-10       Impact factor: 12.079

Review 7.  Antiepileptic drugs and visual function.

Authors:  Alberto Verrotti; Rossella Manco; Sara Matricardi; Emilio Franzoni; Francesco Chiarelli
Journal:  Pediatr Neurol       Date:  2007-06       Impact factor: 3.372

Review 8.  The effect of antiepileptic drugs on visual performance.

Authors:  Emma J Roff Hilton; Sarah L Hosking; Tim Betts
Journal:  Seizure       Date:  2004-03       Impact factor: 3.184

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.